Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014

Several trials suggest that triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) and biologic disease‐modifying antirheumatic drugs (DMARDs) have similar efficacy in patients with rheumatoid arthritis (RA). This study was undertaken to investigate intensification to triple therapy after initial nonbiologic prescription among patients with RA.

[1]  J. O'dell,et al.  Therapies for Active Rheumatoid Arthritis after Methotrexate Failure , 2017 .

[2]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[3]  藤井隆夫.  Treating rheumatoid arthritis to the target―関節リウマチの治療戦略をここまで変えたものは何か― , 2016 .

[4]  D. Collier,et al.  Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis , 2015, Arthritis care & research.

[5]  M. Bonafede,et al.  Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis , 2015, Journal of medical economics.

[6]  M. Neovius,et al.  Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial , 2014, Annals of the rheumatic diseases.

[7]  A. Wailoo,et al.  Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. , 2014, Rheumatology.

[8]  D. van Zeben,et al.  Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial , 2014, Annals of the rheumatic diseases.

[9]  M. Neovius,et al.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial , 2012, Annals of the rheumatic diseases.

[10]  Jeffrey R Curtis,et al.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. , 2012, Arthritis and rheumatism.

[11]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[12]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[13]  Jeffrey N Katz,et al.  Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.

[14]  M. Wörnert,et al.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial , 2009, The Lancet.

[15]  J. Allison,et al.  Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. , 2009, Journal of clinical epidemiology.

[16]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.